Telesis Bio, Inc. TBIO

Company Overview

Telesis Bio, Inc. (NASDAQ: TBIO) is a U.S.-based synthetic biology company focused on automating the design, synthesis, and production of synthetic DNA and related biological materials for research, therapeutic development, and industrial biotechnology applications. The company operates within the broader life sciences, synthetic biology, and laboratory automation industries, serving biotechnology companies, pharmaceutical developers, academic research institutions, and government laboratories. Its core business centers on enabling rapid and automated DNA and mRNA synthesis workflows intended to accelerate biological discovery and development timelines.

The company’s primary revenue drivers have historically included sales of automated biofoundry instruments, consumables, reagents, software-enabled workflow solutions, and synthetic biology services. Telesis Bio is known for integrating hardware, software, and chemistry into end-to-end platforms that automate synthetic biology processes. The company evolved from Codex DNA, Inc., which was founded to commercialize enzymatic DNA synthesis technologies and automated biological engineering systems. In 2023, the company rebranded to Telesis Bio to reflect a broader strategic focus beyond DNA synthesis toward integrated synthetic biology infrastructure and applications.